Find Reports
Select Report Type
Reimbursement Review
Displaying 1351 - 1375 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| pembrolizumab | Keytruda | pembrolizumab | Primary mediastinal B-cell lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0034-000 | |||
| olaparib | Lynparza | olaparib | Breast Cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0013-000 | |||
| icatibant | Firazyr | icatibant | Acute attacks of hereditary angioedema | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0014-000 | |||
| vorinostat | Zolinza | vorinostat | Cutaneous T-cell lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0015-000 | |||
| baloxavir marboxil | Xofluza | baloxavir marboxil | Influenza | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0016-000 | |||
| talazoparib | Talzenna | talazoparib | Breast Cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0017-000 | |||
| mepolizumab | Nucala | mepolizumab | Eosinophilic granulomatosis with polyangiitis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0018-000 | |||
| galcanezumab | Emgality | galcanezumab | Episodic cluster headache | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0019-000 | |||
| clofarabine | Clolar | clofarabine | Acute lymphoblastic leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0020-000 | |||
| dapagliflozin | Forxiga | dapagliflozin | Chronic kidney disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0021-000 | |||
| Rivaroxaban (granules for oral... | Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0022-000 | |||
| glecaprevir / pibrentasvir | Maviret | glecaprevir / pibrentasvir | Hepatitis C, chronic | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0023-000 | |||
| sofosbuvir / velpatasvir | Epclusa | sofosbuvir / velpatasvir | Hepatitis C, chronic | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0024-000 | |||
| fluticasone furoate/umeclidini... | Trelegy Ellipta | fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | Asthma, maintenance | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0025-000 | |||
| omalizumab | Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0026-000 | |||
| mepolizumab | Nucala | mepolizumab | Asthma, severe eosinophilic (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0027-000 | |||
| dabrafenib and trametinib | Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric high-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0028-000 | |||
| dabrafenib and trametinib | Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric low-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0029-000 | |||
| treosulfan | Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0030-000 | |||
| daratumumab | Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0031-000 | |||
| liraglutide | Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0032-000 | |||
| dexamethasone intravitreal imp... | Ozurdex | dexamethasone intravitreal implant | Non-infectious uveitis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0033-000 | |||
| trastuzumab deruxtecan | Enhertu | trastuzumab deruxtecan | Metastatic HER2-positive breast cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0035-000 | |||
| capmatinib | Tabrecta | capmatinib | Metastatic non-small cell lung cancer (NSCLC) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0036-000 | |||
| solriamfetol | Sunosi | solriamfetol | Excessive daytime sleepiness | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0039-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1351 - 1375 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81